Related Experiment Video

Updated: Jul 23, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Growth in asthmatic children treated with fluticasone propionate. Fluticasone Propionate Asthma Study Group

D B Allen1, E A Bronsky, C F LaForce

  • 1University of Wisconsin Children's Hospital, Madison 53792-4108, USA.

The Journal of Pediatrics
|April 17, 1998
PubMed

Insights

Inhaled fluticasone propionate did not affect growth in children with persistent asthma. Studies show similar growth rates compared to placebo over one year in prepubescent children.

Area of Science:

  • Pediatric pulmonology
  • Pharmacological effects on growth
  • Asthma management

Background:

  • Persistent asthma affects children's quality of life.
  • Inhaled corticosteroids are a common asthma treatment.
  • Concerns exist regarding potential growth suppression in children.

Purpose of the Study:

  • To evaluate the long-term impact of inhaled fluticasone propionate on growth in children with persistent asthma.
  • To compare growth rates in children treated with different doses of fluticasone propionate versus placebo.

Main Methods:

  • A double-blind, randomized, placebo-controlled trial involving 325 prepubescent children.
  • Children received either placebo or inhaled fluticasone propionate (50 or 100 microg twice daily) for one year.
  • Monthly growth assessments and periodic pulmonary function tests were conducted.

Main Results:

  • No statistically significant differences in mean height, growth velocity, or skeletal age were observed between treatment groups.
  • Mean height increase over one year was comparable across placebo, 50 microg, and 100 microg fluticasone propionate groups.
  • The overall p-value for height increase was 0.308, indicating no significant treatment effect.

Conclusions:

  • Inhaled fluticasone propionate at 50 and 100 microg twice daily for one year did not adversely affect growth in prepubescent children with persistent asthma.
  • Growth rates were similar to those of placebo-treated children and consistent with expected velocity for age.
  • These findings support the safety of inhaled fluticasone propionate for growth in pediatric asthma patients.
Abstract

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion05:56

A Traditional Chinese Medicine Characteristic Therapy for Bronchial Asthma: Moxibustion

Published on: May 12, 2023

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...